COST-EFFECTIVENESS ANALYSIS OF ADJUVANT ALECTINIB VERSUS PLATINUM-BASED CHEMOTHERAPY IN RESECTED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER IN THE CHINESE HEALTH CARE SYSTEM

被引：0
|
作者：
Wei, Q. [1 ]
Mao, J. [2 ]
Liang, Y. [2 ]
Guan, X. [2 ]
机构：
[1] Chinese Univ Hong Kong, Sch Pharm, Sha Tin, Hong Kong, Peoples R China
[2] China Pharmaceut Univ, Nanjing, Jiangsu, Peoples R China
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE167
引用
收藏
页码：S86 / S87
页数：2
相关论文
共 50 条
  • [21] Neoadjuvant immunotherapy plus chemotherapy and adjuvant targeted therapy in ALK-positive non-small-cell lung cancer
    Song, Qi
    Li, Jie
    Xiong, Qi
    Long, Ya Ping
    Yang, Bo
    Dong, Zhou Huan
    Liang, Chao Yang
    Yang, Bo
    IMMUNOTHERAPY, 2023, 15 (11) : 809 - 817
  • [22] Cost-effectiveness of adjuvant chemotherapy in resected non-small cell cancer
    Messori, Andrea
    Caccese, Erminia
    Cecchi, Michele
    Orsi, Cecilia
    Tendi, Enrico
    PHARMACY WORLD & SCIENCE, 2007, 29 (05): : 486 - 486
  • [23] Pembrolizumab in Combination With Platinum-Based Chemotherapy in Recurrent EGFR/ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
    Gadgeel, S.
    Dziubek, K.
    Nagasaka, M.
    Braun, T.
    Hassan, K.
    Cheng, H.
    Wozniak, A.
    Halmos, B.
    Stevenson, J.
    Patil, P.
    Pennell, N.
    Fidler, M. J.
    Bonomi, P.
    Qin, A.
    Niu, Z.
    Nagrath, S.
    Kalemkerian, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S863 - S863
  • [24] Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
    Nishio, Makoto
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Tanaka, Tomohiro
    Kuriki, Hiroshi
    Zeaiter, Ali
    Tamura, Tomohide
    LUNG CANCER, 2018, 121 : 37 - 40
  • [25] Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis
    Zhu, Viola W.
    Lu, Yuxin
    Ou, Sai-Hong Ignatius
    CLINICAL LUNG CANCER, 2019, 20 (01) : E77 - E80
  • [26] COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    Erdogan-Ciftci, E.
    Guler, B.
    Orfanos, P.
    VALUE IN HEALTH, 2018, 21 : S40 - S40
  • [27] BRIGATINIB COMPARED WITH CRIZOTINIB AND ALECTINIB IN PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAIN METASTASES AT DIAGNOSIS: A COST-EFFECTIVENESS ANALYSIS FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
    Genov, I
    Mendes da Silva, B.
    Lanchoti Fiori, G. M.
    Villas Boas, B.
    Teixeira Chadid, T.
    Regis, C.
    VALUE IN HEALTH, 2021, 24 : S31 - S32
  • [28] Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer
    Reckamp, Karen L.
    Lin, Huamao M.
    Cranmer, Holly
    Wu, Yanyu
    Zhang, Pingkuan
    Walton, Laura J.
    Kay, Stephen
    Cichewicz, Allie
    Neupane, Binod
    Fahrbach, Kyle
    Popat, Sanjay
    Camidge, D. Ross
    FUTURE ONCOLOGY, 2022, 18 (20) : 2499 - 2510
  • [29] Cost-effectiveness of chemotherapy in non-small-cell lung cancer - In reply
    Leighl, NB
    Shepherd, FA
    Goodwin, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3751 - 3752
  • [30] Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan
    Masuda, Noriyuki
    Ohe, Yuichiro
    Gemma, Akihiko
    Kusumoto, Masahiko
    Yamada, Ikuyo
    Ishii, Tadashi
    Yamamoto, Nobuyuki
    CANCER SCIENCE, 2019, 110 (04) : 1401 - 1407
12345